Danoprevir

Overview

Danoprevir (ITMN-191) is an orally active NS3/4A protease inhibitor for hepatitis C virus ( HCV ) with an IC 50 of 0.29 nM and is selective for NS3/4A over a panel of 53 proteases ( IC 50 higher than 10 μM). Danoprevir (ITMN-191) inhibits HCV genotypes 1a, 1b, 4, 5, and 6 ( IC 50 s=0.2-0.4 nM) as well as 2b and 3a ( IC 50 s=1.6, 3.5 nM). Danoprevir is also a SARS-CoV 3CL pro inhibitor with an IC 50 of 0.05 μM.

Application

Products | Products > Disease Areas > Viral Infection | Products > Disease Areas > SARS-CoV-2 Infection | Products > Disease Areas > Hepatitis C Virus Infection | Products > Disease Areas > Infection | Products > Disease Areas > Coronavirus Infection | Products > Disease Areas > Hepatitis Virus Infection | Products > Signaling Pathways > Anti-infection | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Infection | Products > Signaling Pathways > HCV Protease | Products > Signaling Pathways > HCV | Products > Signaling Pathways > SARS-CoV

Product Information

• Catalog No.: HY-10238
• CAS No.: 850876-88-9
• Molecular Formula: C35H46FN5O9S
• Molecular Weight: 731.83
• Purity: 99.67%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: ≥ 2.5 mg/mL (3.42 mM); Clear solution
• Availability: In-stock

Source

Original product source